Related Experiment Video
Updated: Sep 3, 2025
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline
Irene S Yu1, Francine Aubin2, Rachel Goodwin3
1Department of Medical Oncology, BC Cancer Surrey, Surrey, BC, Canada.
Abstract:
The systemic therapy management of metastatic colorectal cancer (mCRC) has evolved from primarily cytotoxic chemotherapies to now include targeted agents given alone or in combination with chemotherapy, and immune checkpoint inhibitors. A better understanding of the pathogenesis and molecular drivers of colorectal cancer not only aided the development of novel targeted therapies but led to the discovery of tumor mutations which act as predictive biomarkers for therapeutic response. Mutational status of the KRAS gene became the first genomic biomarker to be established as part of standard of care molecular testing, where KRAS mutations within exons 2, 3, and 4 predict a lack of response to anti- epidermal growth factor receptor therapies. Since then, several other biomarkers have become relevant to inform mCRC treatment; however, there are no published Canadian guidelines which reflect the current standards for biomarker testing. This guideline was developed by a pan-Canadian advisory group to provide contemporary, evidence-based recommendations on the minimum acceptable standards for biomarker testing in mCRC, and to describe additional biomarkers for consideration.
Insights
Canadian guidelines for metastatic colorectal cancer (mCRC) biomarker testing are needed. This guideline provides evidence-based recommendations for essential and additional biomarker testing to optimize treatment selection.
Area of Science:
- Oncology
- Molecular Diagnostics
- Genomics
Background:
- Metastatic colorectal cancer (mCRC) treatment has advanced beyond chemotherapy to include targeted agents and immune checkpoint inhibitors.
- Understanding molecular drivers has led to targeted therapies and predictive biomarkers for treatment response.
- KRAS mutations are established biomarkers predicting lack of response to anti-EGFR therapies.
Purpose of the Study:
- To develop contemporary, evidence-based Canadian guidelines for biomarker testing in mCRC.
- To establish minimum acceptable standards for essential biomarker testing.
- To identify additional biomarkers for consideration in mCRC treatment.
Main Methods:
- Development of a guideline by a pan-Canadian advisory group.
- Evidence-based review of current standards for biomarker testing in mCRC.
- Formulation of recommendations for minimum acceptable standards and additional biomarkers.
Main Results:
- Identified a need for updated Canadian guidelines on mCRC biomarker testing.
- Established recommendations for essential biomarker testing standards.
- Described additional relevant biomarkers for consideration in mCRC management.
Conclusions:
- Current mCRC systemic therapy management benefits from molecularly informed treatment selection.
- Standardized biomarker testing is crucial for optimizing therapeutic strategies in mCRC.
- These guidelines provide a framework for Canadian clinicians to implement evidence-based biomarker testing.
